Efficacy and Safety of the Intralesional Cidofovir for Recurrent Respiratory Papillomatosis

Abstract

Objectives : The treatment of recurrent respiratory papillomatosis (RRP) continues to be difficult. We evaluated the benefits and risks of the intralesional administration of cidofovir for severe RRP in 13 patients.

Methods : Thirteen patients received intralesional cidofovir. The surgeries were performed three times every two weeks, with intralesional injections of cidofovir (7.5 mg/ml). A further endoscopic evaluation was made at three months depending on whether there was persistent papillomatosis. The intrelesional injection of cidofovir with CO₂ laser vaporization was performed in the case of persistent papilloma, and treatment was repeated as long as papillomas were observed.

Results : One of 13 patients achieved complete remission and seven achieved partial remission. Five patients showed a poor response to cidofovir. No side effects related to cidofovir were observed in 13 patients.

Conclusion : The results of the study indicate that the intralesional injection of cidofovir can be an effective treatment method for recurrent respiratory papillomatosis.